Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




PerkinElmer Collaborates on Preterm Birth Biomarkers

By HospiMedica staff writers
Posted on 21 Aug 2006
PerkinElmer, Inc. More...
(Wellesley, MA, USA) has announced a multi-year license-and-research agreement with the University of Leicester (Leicester, United Kingdom) under which the two organizations will begin to lay the groundwork for the clinical investigation and discovery of biomarkers that predict preterm birth (PTB). The collaboration will be financed by PerkinElmer.

PerkinElmer will support the expansion of the University of Leicester's maternal health research capabilities and provide advanced tools, technology, and expertise. Professor J. C. Konje, M.D., and colleagues of Leicester University's reproductive sciences section of the department of cancer studies and molecular medicine are dedicated to the study and prediction of preterm birth. The team is conducting research in the field of preterm labor diagnosis.

The partnership will give PerkinElmer broader access within Professor Konje's research group to clinical samples, methodology, and clinical consultancy support in the field of maternal health. The University of Leicester and PerkinElmer will work towards validating any new PTB biomarkers that will complement PerkinElmer's maternal health portfolio. PerkinElmer and the University of Leicester will share access to licensed intellectual property from new PTB biomarkers that result from this research.

It is estimated that preterm labor complicates 6-10% of all pregnancies and is the most common cause of neonatal morbidity and mortality. Worldwide statistics reflect that there may be as many as 13 million preterm births annually, and this figure is predicted to increase. In the United States alone, an estimated U.S.$820 million is spent on preterm hospitalization subsequently shown to have been unnecessary. These hospitalizations tax both the mother's health and healthcare resources.

Currently, there are no rapid or accurate tests that positively predict preterm labor. The aim of the collaboration between PerkinElmer and the University of Leicester is to effectively address this need and eventually design and supply an effective preterm labor test predictor.



Related Links:
PerkinElmer
University of Leicester

Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Sample Transportation System
Tempus1800 Necto
Gel Cards
DG Gel Cards
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.